Clinical and economic impact of high short-acting β-agonist use in patients with persistent asthma
High Short-Acting β−Agonists (SABA) use is an important indicator of poor asthma control and has been utilized in various studies as a proxy measure of asthma control for various purposes (e.g. predictive marker for future exacerbation events). However, little evidence exists with regard to the optimal measurement of high SABA use for predicting future exacerbation events as well as the impact of asthma control, as measured by high SABA use and other characteristics, on Health Related Quality of Life (HRQoL) and Health Resource Utilization (HRU). The objective of this research was to determine ...
(For more, see "View full record.")